Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down Following Analyst Downgrade

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price gapped down prior to trading on Wednesday after Zacks Research downgraded the stock from a hold rating to a strong sell rating. The stock had previously closed at $17.92, but opened at $17.26. Daiichi Sankyo shares last traded at $18.1650, with a volume of 3,337 shares traded.

Separately, Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Daiichi Sankyo has a consensus rating of “Reduce”.

Daiichi Sankyo Trading Up 1.2%

The stock has a market cap of $33.74 billion, a price-to-earnings ratio of 21.06, a price-to-earnings-growth ratio of 1.91 and a beta of -0.11. The firm’s 50 day moving average is $17.81 and its two-hundred day moving average is $17.16. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Equities analysts anticipate that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.